Escitalopram Oxalate

Catalog No.S4064

For research use only.

Escitalopram Oxalate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) with Ki of 0.89 nM.

Escitalopram Oxalate Chemical Structure

CAS No. 219861-08-2

Purity & Quality Control

Choose Selective Serotonin Transporter Inhibitors

Biological Activity

Description Escitalopram Oxalate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) with Ki of 0.89 nM.
Targets
5-HT [2]
0.89 nM(Ki)
In vitro

Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.[1] In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram is found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase. [2]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 83 mg/mL
(200.27 mM)
Water 25 mg/mL
(60.32 mM)
Ethanol Insoluble

Chemical Information

Molecular Weight 414.43
Formula

C20H21FN2O.C2H2O4

CAS No. 219861-08-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04239339 Active not recruiting Drug: Escitalopram 20 mg|Drug: Placebo Healthy Rigshospitalet Denmark|University of Cambridge|Lundbeck Foundation April 28 2020 Phase 4
NCT03912974 Completed Drug: Escitalopram|Drug: Placebo oral capsule Healthy University Hospital Basel Switzerland July 4 2019 Phase 1
NCT03460379 Recruiting Drug: Escitalopram Obesity Morbid Norwegian University of Science and Technology|St. Olavs Hospital|Volvat Medisinsk Senter Stokkan|Namsos Hospital|Alesund Hospital November 2 2016 --
NCT02865642 Recruiting Drug: Serotonin Uptake Inhibitors|Drug: Placebo Stroke University Hospital Inselspital Berne|Cantonal Hospital of St. Gallen August 2016 Phase 2
NCT04013464 Completed Drug: Escitalopram Depressive Disorder Major Peking University Sixth Hospital|National Institute on Drug Dependence China May 1 2016 Not Applicable
NCT02818751 Completed Drug: Escitalopram|Other: Placebo Anxiety University of Cincinnati|National Institute of Mental Health (NIMH) May 2015 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Escitalopram Oxalate | Escitalopram Oxalate supplier | purchase Escitalopram Oxalate | Escitalopram Oxalate cost | Escitalopram Oxalate manufacturer | order Escitalopram Oxalate | Escitalopram Oxalate distributor